How to choose antihypertensive medication in the OPD

Choosing an antihypertensive medication in the outpatient department (OPD) relies on a stepwise approach driven by the patient’s baseline blood pressure, compelling comorbidities, and demographic factors, aligning with major international guidelines.

Unless a specific indication dictates otherwise, initial treatment revolves around three primary classes: ACE inhibitors/ARBs (A), Calcium Channel Blockers (C), and Thiazide/Thiazide-like diuretics (D). Beta-blockers are generally reserved for specific cardiovascular indications rather than first-line, uncomplicated hypertension.

1. Initial Strategy: Monotherapy vs. Combination

• Monotherapy: Appropriate for patients with low-risk, grade 1 hypertension (e.g., <150/90 mmHg) or very elderly/frail patients. Any of the primary classes (A, C, or D) can be used.
• Initial Dual Therapy: Recommended for most patients with BP >20/10 mmHg above their target, or those with high cardiovascular risk. A single-pill combination (SPC) is strongly preferred to maximize medication adherence.
  • Preferred combinations: ACEi/ARB + CCB or ACEi/ARB + Diuretic.

2. Compelling Clinical Indications

When co-morbidities are present, the choice of agent shifts to address both blood pressure and the underlying disease pathology.

Co-morbidity	Preferred Initial Agents	Clinical Rationale & Cautions
HFrEF	ARNI or ACEi/ARB + Beta-blocker + MRA + SGLT2i	Core GDMT. Avoid non-DHP CCBs (Verapamil, Diltiazem) due to negative inotropy.
Coronary Artery Disease	Beta-blocker + ACEi/ARB	Reduces myocardial oxygen demand and prevents adverse ventricular remodeling. Add DHP-CCB for persistent angina.
CKD (with albuminuria)	ACEi or ARB	Dilates efferent arteriole, reducing intraglomerular pressure and proteinuria.
Atrial Fibrillation	Beta-blocker or Non-DHP CCB	Provides simultaneous ventricular rate control.
Diabetes Mellitus	ACEi/ARB, CCB, or Diuretic	ACEi/ARB is mandatory if microalbuminuria is present to delay nephropathy progression.
BPH	Alpha-1 blockers (e.g., Prazosin)	Should be used as an add-on therapy, not monotherapy, due to heart failure risks (ALLHAT trial).

3. Specific Demographic Considerations

• Age and Race: Elderly patients and Black patients often exhibit low-renin hypertension and generally show more robust blood pressure reductions with CCBs or Thiazide-like diuretics (e.g., Chlorthalidone, Indapamide) as initial monotherapy compared to RAS inhibitors.
• Women of Childbearing Potential: ACEi, ARBs, and direct renin inhibitors are strictly contraindicated if planning pregnancy due to teratogenicity. Safe alternatives include Labetalol, Nifedipine, or Methyldopa.

4. OPD Titration and Monitoring

When initiating or adjusting an antihypertensive, follow-up should typically occur within 2 to 4 weeks.

If initiating an ACEi, ARB, or diuretic, a basic metabolic panel (serum creatinine and potassium) must be checked within 1 to 2 weeks. A mild bump in creatinine (up to 30% from baseline) after starting an ACEi/ARB is physiologically expected due to altered intrarenal hemodynamics (but requires very careful monitoring) and does not mandate drug discontinuation unless it is progressive or accompanied by hyperkalemia.